Pharmacokinetics, safety, and activity of trabectedin as first‐line treatment in elderly patients who are affected by advanced sarcoma and are unfit to receive standard chemotherapy: A phase 2 study (TR1US study) from the Italian Sarcoma Group-Reference-Cited by-同舟云学术

Pharmacokinetics, safety, and activity of trabectedin as first‐line treatment in elderly patients who are affected by advanced sarcoma and are unfit to receive standard chemotherapy: A phase 2 study (TR1US study) from the Italian Sarcoma Group

Published:2020-08-04 Issue:21 Volume:126 Page:4726-4734
ISSN:0008-543X
Container-title:Cancer
language:en
Short-container-title:Cancer

Author:

Grosso Federica¹,D’Ambrosio Lorenzo²³,Zucchetti Massimo⁴,Ibrahim Toni⁵,Tamberi Stefano⁶,Matteo Cristina⁴,Rulli Eliana⁴^ORCID,Comandini Danila⁷,Palmerini Emanuela⁸,Baldi Giacomo Giulio⁹,DeCensi Andrea¹⁰,Bergaglio Marina¹¹,Marra Domenico¹⁰,Marchesi Emanuela²,Siri Giacomo¹²¹³,D’Incalci Maurizio⁴,Grignani Giovanni²^ORCID

Affiliation:

1. Mesothelioma and Rare Cancer Unit Azienda Ospedaliera SS Antonio e Biagio General Hospital Alessandria Italy

2. Division of Medical Oncology Candiolo Cancer Institute, FPO–IRCCS Candiolo Italy

3. Department of Oncology University of Torino Orbassano Italy

4. Department of Oncology Istituto di Ricerche Farmacologiche Mario Negri IRCCS Milano Italy

5. Osteoncology and Rare Tumors Center Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS Meldola Italy

6. Oncology Unit Ospedale Per Gli Infermi Faenza Italy

7. Ospedale Policlinico San Martino Genova Italy

8. Chemoterapy Unit IRCCS Istituto Ortopedico Rizzoli Bologna Italy

9. Medical Oncology Department “Santo Stefano” Hospital Prato Italy

10. Division of Medical Oncology Unit EO Ospedali Galliera Genova Italy

11. Oncology Unit Villa Scassi Hospital, ASL3 Genovese Genova Italy

12. Department of Mathematics University of Genoa Genova Italy

13. E.O. Ospedali GallieraScientific Directorate Genova Italy

Funder

PharmaMar

Publisher

Wiley

Subject

Cancer Research,Oncology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/cncr.33120

Reference31 articles.

1. Cancer incidence and mortality in the United States, 1973‐77;Young JL;Natl Cancer Inst Monogr,1981

2. Doxorubicin alone versus intensified doxorubicin plus ifosfamide for first-line treatment of advanced or metastatic soft-tissue sarcoma: a randomised controlled phase 3 trial

3. High-dose ifosfamide in bone and soft tissue sarcomas: results of phase II and pilot studies--dose-response and schedule dependence.

4. Single‐agent ifosfamide studies in sarcomas of soft tissue and bone: the M.D. Anderson experience;Benjamin RS;Cancer Chemother Pharmacol,1993

Cited by 23 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Rehabilitation for Functioning and Quality of Life in Patients with Malignant Pleural Mesothelioma: A Scoping Review;Current Oncology;2024-07-30

2. Trabectedin may be a valuable treatment option for elderly patients with metastatic soft tissue sarcomas;Frontiers in Oncology;2024-07-25

3. Comprehensive Pulmonary Rehabilitation for Patients with Malignant Pleural Mesothelioma: A Feasibility Pilot Study;Cancers;2024-05-26

4. Geriatric Assessment of Older Patients Receiving Trabectedin in First-Line Treatment for Advanced Soft Tissue Sarcomas: The E-TRAB Study from The German Interdisciplinary Sarcoma Group (GISG-13);Cancers;2024-01-28

5. Pharmacometabolomics of trabectedin in metastatic soft tissue sarcoma patients;Frontiers in Pharmacology;2023-08-11